← Leaderboards
Brian J Soher
Duke University
$2,568,106
Attributed
$4,439,116
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $462.3K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,439,116 · 4
By mechanism
R01$4,439,116 · 4
Top collaborators
- Katherine B Peters4 shared
- Manal F. Abdelmalek3 shared
- Karl A Young3 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- Kathryn R Nightingale$16,760,750
- Darell D Bigner$25,397,506
- Cheryl D Bushnell$4,197,850
- Gregg E. Trahey$23,375,787
Others in their field
Top investigators on “Magnetic Resonance Imaging”
- Michael W Weiner · Northern California Institute Res &Educ$151,227,246
- Paul S. Aisen · Cognition Therapeutics, Inc.$114,102,468
- Reisa A. Sperling · Banner Health$112,709,449
- Randall J Bateman · Washington University$108,056,165
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
Magnetic Resonance ImagingMagnetic Resonance SpectroscopyBrain NeoplasmsClinical TrialsBaseProtocols DocumentationMeasurementEvaluationDesignPublic Health RelevanceMorbidity - Disease RateImageMagnetic ResonanceReportingMetabolicSerumNeoplastic CellMutationPhase I TrialModificationMonitorIsocitrate DehydrogenaseGliomaComputerized Data Processing
Grant awards (12)
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$438,208
R01 · FY2025 · CA · contact PI
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$291,737
R01 · FY2024 · CA · contact PI
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$462,296
R01 · FY2023 · CA · contact PI
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma$392,725
R01 · FY2022 · CA · contact PI
Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas$337,891
R01 · FY2018 · CA · contact PI
Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas$359,205
R01 · FY2017 · CA · contact PI
Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD$314,000
R01 · FY2014 · DK · contact PI
Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD$303,010
R01 · FY2013 · DK · contact PI
Impact of Fructose on Metabolism, Energy Homeostasis and MR biomarkers in NAFLD$296,900
R01 · FY2012 · DK · contact PI
MrSPA: Integrated tools and development platform for magnetic resonance research$419,795
R01 · FY2010 · EB · contact PI
MrSPA: Integrated tools and development platform for magnetic resonance research$408,121
R01 · FY2009 · EB · contact PI
MrSPA: Integrated tools and development platform for magnetic resonance research$415,228
R01 · FY2008 · EB · contact PI